Skip to main content

My New Space

High pathogenicity avian #influenza in #pinniped #conservation

By G.M.
  Abstract Since 2020, H5Nx high pathogenicity avian influenza viruses (HPAIVs) have caused widespread disruptions not only to global agriculture and trade but also to the health of free-ranging wildlife . Pinnipeds have experienced greater mortality from H5Nx HPAIV than any other mammalian taxa . Emergent virus strains, persisting over long time periods and vast geographic distances , have repeatedly triggered large-scale mortality events in pinniped populations. Of particular concern is the spread of H5Nx HPAIV to the Southern Hemisphere —including the emergence of a marine mammal-adapted clade in South America and detections in the sub-Antarctic and Antarctic —and to other remote locations such as the Hawaiian Islands . These developments elevate concern for the world’s endangered, isolated and endemic pinnipeds . While managing HPAIV in any animal population is a formidable task, working with free-ranging marine mammals poses unique challenges. In this review and perspective pi...
Post a Comment

#Influenza and Other Respiratory Viruses #Research #References (by AMEDEO, March 7 '26)

Image
By G.M.

 


    Ann Intern Med

  1. SACKS HS
    In older adults, high- vs. standard-dose influenza vaccine reduced hospitalization for influenza or pneumonia in those with CKD.
    Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-26-00324.
    PubMed         Abstract available

  2. ANAND R, Glatt AE
    In healthy adults, a modified RNA vs. inactivated influenza vaccine reduced laboratory-confirmed influenza-like illness at >/=14 d.
    Ann Intern Med. 2026 Mar 3. doi: 10.7326/ANNALS-25-05681.
    PubMed         Abstract available


    Antiviral Res

  3. RUDRAMURTHY GR, Gudla CS, Harisha R, Selvam V, et al
    FNDR-11124, a broad-spectrum small molecule inhibitor of viral RNA polymerase, restricts replication of SARS-CoV-2 and Influenza virus in vitro and in vivo.
    Antiviral Res. 2026 Mar 2:106382. doi: 10.1016/j.antiviral.2026.106382.
    PubMed         Abstract available


    Arch Virol

  4. DUTTA M, Sarmah N, Siddique AI, Borah P, et al
    Temporal trends and burden of influenza B virus lineages in Dibrugarh, Assam (2014-2025): predominance of Victoria with early circulation of Yamagata.
    Arch Virol. 2026;171:110.
    PubMed        


    J Gen Virol

  5. GROSS J, Pouget B, Sarrat M, Foret-Lucas C, et al
    In vivo inhibition of JAK-STAT signalling enhances high pathogenicity influenza virus replication in ducks.
    J Gen Virol. 2026;107:002238.
    PubMed         Abstract available


    J Immunol

  6. WERNINGHAUS IC, Hinke DM, Katta K, Bogen B, et al
    A combinatorial DNA vaccine encoding APC-targeted, bivalent HA and NA antigens results in an improved influenza vaccine.
    J Immunol. 2026;215:vkaf378.
    PubMed         Abstract available

  7. SHARMA SB, Kumar K, Parchment N, Eggleston T, et al
    Viral-specific induction of cellular and soluble urokinase plasminogen activator receptor (suPAR) expression.
    J Immunol. 2026;215:vkaf365.
    PubMed         Abstract available

  8. SOUDANI N, Sidney J, Da Silva Antunes R, Case JB, et al
    Identification of immunodominant T cell epitopes in SARS-CoV-2 spike protein in Syrian hamsters.
    J Immunol. 2026;215:vkaf342.
    PubMed         Abstract available


    J Infect Dis

  9. WANG L, Wang J, Hossain J, Cooper HC, et al
    Development and Characterization of Candidate Vaccine Viruses against High Pathogenicity Avian Influenza A(H5) Viruses for Rapid Pandemic Response.
    J Infect Dis. 2026 Feb 28:jiag132. doi: 10.1093.
    PubMed         Abstract available


    N Engl J Med

  10. GABET A, Bernard C, Zureik M
    Updated Evidence Base for Covid-19, RSV, and Influenza Immunizations.
    N Engl J Med. 2026;394:10.
    PubMed        


    Pediatrics

  11. TSUNG S, Zeng YB, Shah K, Asch SM, et al
    Cost-Effectiveness of Nirsevimab and Maternal RSVpreF Immunization Strategies in Low-Risk Infants.
    Pediatrics. 2026 Feb 20:e2025071558. doi: 10.1542/peds.2025-071558.
    PubMed         Abstract available


    PLoS Comput Biol

  12. CRAIG M, Deng X, McLeod DV
    Viral evolution during primary infection in immunocompromised hosts.
    PLoS Comput Biol. 2026;22:e1013967.
    PubMed         Abstract available


    PLoS One

  13. RAHIMNAHAL S, Yousefizadeh S, Mohammadi Y
    Designing a novel vaccine against COVID-19 based on spike SARS-Cov-2 notable mutations using immunoinformatics approaches.
    PLoS One. 2026;21:e0334662.
    PubMed         Abstract available

  14. RATREE S, Assavapokee N, Santibenchakul S, Sirisabya N, et al
    Reported adverse events following COVID-19 vaccination in gynecologic cancer patients in Thailand: A descriptive study.
    PLoS One. 2026;21:e0342303.
    PubMed         Abstract available

  15. DEMPSEY LF, Osuka H, McGovern OL, Munita JM, et al
    Antimicrobial use and documented infection among hospitalized adults in South American acute care facilities during the coronavirus disease 2019 (COVID-19) pandemic.
    PLoS One. 2026;21:e0343535.
    PubMed         Abstract available

  16. SHKOLNIKOV VM, Timonin S, Jdanov D, Medina-Jaudes N, et al
    Widening East-West inequality in life expectancy in Europe during the COVID-19 pandemic: An international comparative study.
    PLoS One. 2026;21:e0344003.
    PubMed         Abstract available

  17. MEYER F, Traidl S, Ameri M, Dreher A, et al
    Distinguishing post-COVID from long-COVID in adults: Development and validation of a biomarker signature using targeted proteomics and machine learning in a cross-sectional observational study.
    PLoS One. 2026;21:e0338451.
    PubMed         Abstract available

  18. FIAZ N, Basheer A, Zahoor I, Naveed S, et al
    Distinct mutational landscapes and phylogenomic insights of the SARS-CoV-2 delta variant in Pakistan and India: Regional evolution, novel mutations, and epidemiological implications.
    PLoS One. 2026;21:e0340704.
    PubMed         Abstract available

  19. GUTIERREZ-SIGUT E, Lamarche V, Rowley K, Lago EF, et al
    Access to information in deaf and hard-of-hearing people.
    PLoS One. 2026;21:e0343904.
    PubMed         Abstract available

  20. PAVON R, Parra S, Rubio FJ, Feliu M, et al
    Assessment of physical status and analysis of lipidomic and metabolomic alterations in patients with Post-COVID-19 condition.
    PLoS One. 2026;21:e0341192.
    PubMed         Abstract available


    Virology

  21. BARMAN S, Iyengar R, Miller L, Turner JCM, et al
    Reverse genetic rescue and propagation of human influenza A(H3N2) master virus seed in HEK-293 suspension cells.
    Virology. 2026;618:110862.
    PubMed         Abstract available
Labels:

Comments

Post a Comment

Popular posts from this blog

#Neuroinvasive #Oropouche virus in a patient with #HIV from extra-Amazonian #Brazil

By G.M.
{Excerpt} A novel reassortant Oropouche virus (OROV) lineage (with medium [M], large [L], and small [S] RNA segments : M1L2S2) has driven Brazil's largest and most geographically widespread OROV epidemic , expanding beyond the endemic Amazon basin to establish local transmission across multiple Brazilian states and other previously unaffected Latin American countries . The rapid spread of this lineage underscores its evolutionary potential and reinforces its significance as a public health threat .1 Similar to chikungunya and Zika viruses, expanding arboviruses can exhibit unexpected clinical and epidemiological shifts , including vertical transmissions , neuroinvasive effects, and potentially fatal outcomes.2–4 Although OROV typically causes self-limited febrile illness, accumulating clinical and experimental evidence suggests neurotropic potential .5 This Correspondence describes the first confirmed case of neuroinvasive OROV infection caused by the emergent M1L2S2 lineage in ext...
Post a Comment
Read more »

No evidence of immune #exhaustion after repeated #SARS-CoV-2 #vaccination in vulnerable and healthy populations

By G.M.
Abstract Frequent SARS-CoV-2 vaccination in vulnerable populations has raised concerns that this may contribute to T cell exhaustion , which could negatively affect the quality of immune protection. Herein, we examined the impact of repeated SARS-CoV-2 vaccination on T cell phenotypic and functional exhaustion in frail older adults in long-term care (n = 23), individuals on immunosuppressive drugs (n = 10), and healthy adults (n = 43), in Canada . Spike-specific CD4+ and CD8+ T cell levels did not decline in any cohort following repeated SARS-CoV-2 vaccination, nor did the expression of exhaustion markers on spike-specific or total T cells increase. T cell production of multiple cytokines (i.e. polyfunctionality) in response to the spike protein of SARS-CoV-2 did not decline in any cohort following repeated vaccination. None of the cohorts displayed elevated levels of terminally differentiated T cells following multiple SARS-CoV-2 vaccinations. Thus, repeated SARS-CoV-2 vaccination was...
Post a Comment
Read more »

Chimeric #hemagglutinin and #M2 #mRNA #vaccine for broad #influenza subtype protection

By G.M.
Abstract Since multiple and unpredicted influenza viruses cause seasonal epidemics and even high-risk pandemics , developing a universal influenza vaccine is essential to provide broad protection against various influenza subtypes. Combined with the mRNA lipid nanoparticle-encapsulated (mRNA-LNP) vaccine platform and chimeric immunogen strategy , we developed a novel cocktail mRNA vaccine encoding chimeric HAs (cH5/1-BV, cH7/3) and intact M2 (termed Fluaxe), which confers broad protection against major circulating IAVs and IBVs , as well as highly pathogenic avian influenza . Two-dose intramuscular immunization of Fluaxe in mice elicited cross-reactive neutralizing antibodies , T cell responses, and long-lived immunity, resulting in robust protection against multiple lethal influenza virus infections and severe acute lung injuries . In particular, intramuscular administration stimulated systemic immunity together with a prominent lung tropism of memory cells . Moreover, Fluaxe immuniza...
Post a Comment
Read more »